2024-02-272024-02-272008-12Başkan, E. B. (2008). "Biologic agents in psoriasis". Turkderm Deri Hastaliklari ve Frengi Arsivi, 40(Supplement 2), 42-501019-214X1308-6294https://hdl.handle.net/11452/39986Psoriasis is a chronic, inflammatory disease affecting 1-3% of population. Advances in the pathogenesis of psoriasis and biotechnology have led to the development of targeted therapy named biologic agents. in this review, general information on biologic drugs are presented and literature on four biologic agents available in our country for moderate to severe plaque psoriasis has been summarized. Mechanisms of action, indications and dosage, results of clinical studies and safety profiles of each biologic agent are discussed.eninfo:eu-repo/semantics/closedAccessDermatologyAdalimumabBiologicsEfalizumabEtanerceptInfliximabPsoriasisChronic plaque psoriasisRandomized controlled-trialPatient-reported outcomesLong-termtreatmentPhase-IIIDouble-blindEfalizumab therapyRheumatoid-arthritisOpen-labelInfliximab monotherapyArticle0002631699000062-s2.0-63149181435425042Supplement 2DermatologyPustulosis Palmoplantaris; Ustekinumab; EtanerceptAdalimumabAlefaceptAntipsoriasis agentEfalizumabEtanerceptInfliximabTumor necrosis factor alpha inhibitorBiotechnologyClinical researchDisease severityDrug indicationDrug mechanismDrug safetyHumanPathogenesisPsoriasisReview